Gene therapy injection aims to heal diabetic foot sores
NCT ID NCT07391319
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial is testing a drug called Neovasculgen, given as injections into the leg muscles, to see if it can help heal foot ulcers in people with diabetes. The study will include 144 adults with type 1 or type 2 diabetes who have a non-healing foot ulcer. Participants will receive either Neovasculgen or a placebo, and researchers will track how many ulcers heal completely within about 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Neovasculgen (a gene therapy drug given as injections into the leg muscles)
What this could lead to
If it works, this could provide a new treatment option to help heal stubborn foot ulcers in people with diabetes, potentially reducing the risk of amputation.
What could go wrong
This is still an early-stage Phase 3 trial with only 144 participants, so results may not apply to everyone. The drug is injected into the muscle and may cause side effects like pain or swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Botkin Hospital
RECRUITINGMoscow, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••